MedTrace Logo

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

NCT07076706 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-03-03

No results posted yet for this study

Summary

The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.

Conditions

  • Male Pattern of Hair Loss, Androgenic Alopecia
  • Androgenetic Alopecia (AGA)

Interventions

DRUG

minoxidil + finasteride

topical foam: 5%minoxidil+0.075%finasteride

DRUG

minoxidil + finasteride

topical foam: 5%minoxidil+0.1%finasteride

DRUG

Placebo foam

Topical placebo foam

Sponsors & Collaborators

  • Beijing Dayspring Pharmaceutical Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Jianzhong Zhang, MD, PhD · Peking University People's Hospital

  • Cheng Zhou, MD, PhD · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-05
Primary Completion
2025-08-26
Completion
2025-09-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07076706 on ClinicalTrials.gov